Riskpilot← Back to searchSign inGet full accessWahTsui Biotech AB
ABActiveOrg 5593516593Nanna Svartz Väg 4Activities of agents involved in the wholesale of other particular products · NACE 4618Est. 20210 employees
Revenue 2024
—
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2024
—
0 employees
| Revenue | — | — |
| EBITDA | SEK 0 | — |
| Net profit | — | — |
| Total assets | — | — |
| Equity | — | — |
| Employees | 0 | — |
Legal name
WahTsui Biotech AB
Org number
5593516593
Legal form
Aktiebolag
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
7 december 2021
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget kommer att Engagerad i biomedicinsk forskning och FoU- ledning. Göra cancerforskning, antiviral läkemedelsutveckling och screening. Bolaget kommer att förse bioteknikföretag med experimentell teknikutveckling, experimintellt teknikutbyte (inklusive FoU- personalmöten och besök), överföring av experimentell teknik och FoU-resultat (återförsäljning till kunder), informations konsulttjänster etc. efter kunders behov. Forskning och utveckling, produktion, försäljning och import och export av kosmetika, läkemedel och hälsokost. Produkter utvecklade eller representerade av företaget kommer att säljas online. Ge kunderna inspektions- och Testtjänster. Annonsdesign, produktion och byråtjänster.
Address
Nanna Svartz Väg 4
Email
info@wahtsuibiotech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | — | 1 602 | — |
| Staff expenses | — | — | — |
| EBITDA | 0 | 382 | 0 |
| Depreciation & amort. | — | −0 | — |
| EBIT | 0 | 382 | 0 |
| Net financials | — | — | — |
| Profit before tax | 0 | 382 | 0 |
| Tax | — | −0 | — |
| Net profit | — | 382 | — |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | — | 454 | — |
| Equity | — | 454 | — |
| Long-term debt | — | 0 | — |
| Short-term debt | — | 0 | — |
| Total debt | — | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20222024
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20222024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20222024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LW Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
| Former (1) | ||
YS Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
WL | Chairman | 2022 |
| Former (1) | ||
| Deputy Board Member | 2024 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of WahTsui Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lingli Wang | Deputy Chief Executive Officer | 0 companies |
| Yan Song | Deputy Chief Executive Officer | 0 companies |
| Shiyao Yi | Deputy Board Member | 0 companies |
| Linxiao Zhang | Deputy Board Member | 0 companies |
| Wen Liu | Chairman | 0 companies |